Juva Life Inc (CSE:JUVA, OTCQB:JUVAF). CEO Doug Chloupek tells Proactive that the Vancouver, Canada-based company has identified a second, non-cannabinoid proprietary compound, JUVA-041, which he says has anti-inflammatory properties.
Chloupek says JUVA-041 is the second molecule it has now has identified, complementing JUVA-019. Next steps include conducting additional studies to understand its commercial viability as well as advance conversations with potential licensing partners.